Risk Mitigation Measures for Coronavirus Disease 2019

被引:0
作者
Lu, Yujia [1 ]
Zhou, Ruke [2 ]
Zhang, Heran [3 ]
机构
[1] Southwest Univ, Coll Westa, Chongqing, Peoples R China
[2] Wuhan Univ, Sch Hlth Sci, Wuhan, Hubei, Peoples R China
[3] China Pharmaceut Univ, Coll Life Sci & Technol, Nanjing, Jiangsu, Peoples R China
来源
2020 INTERNATIONAL CONFERENCE ON GREEN DEVELOPMENT AND ENVIRONMENTAL SCIENCE AND TECHNOLOGY | 2020年 / 615卷
关键词
SARS-COV-2; VACCINES;
D O I
10.1088/1755-1315/615/1/012014
中图分类号
S2 [农业工程];
学科分类号
0828 ;
摘要
Since December 2019, Coronavirus disease 2019 (COVID-19) broke out in China and soon spread worldwide. The once-in-a-century pandemic brought unexpected effect on both economy and health globally. Up to August 12, 2020, more than 20 million cases have been diagnosed across nearly 200 countries. In some countries such as the United States and India, confirmed cases are still increasing substantially. However, China, as the most severe one in the early stage of the outbreak, has curbed epidemic and saved lives rapidly. The intention of this review is to discuss effective risk mitigation measures, with the main focus on those applied in China, aiming to provide actionable and achievable guidance for the fight against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the world. We analyzed, evaluated and summarized the crucial strategies, including risk communication, quarantine and isolation, vaccine and antiviral administration. The above risk mitigation measures have proven to be effective in fighting against the epidemic in China. In light of specific conditions, we believe these effective risk mitigation measures can be well applied in other countries. In this paper, we will analyze the solution to control the worldwide pandemic and even the epidemic occurring in the future.
引用
收藏
页数:14
相关论文
共 35 条
[1]   Treatment of SARS-CoV-2: How far have we reached? [J].
Ahsan, Waquar ;
Javed, Shamama ;
Al Bratty, Mohammed ;
Alhazmi, Hassan A. ;
Najmi, Asim .
DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (02) :67-72
[2]   SARS-CoV-2 Vaccines: Status Report [J].
Amanat, Fatima ;
Krammer, Florian .
IMMUNITY, 2020, 52 (04) :583-589
[3]  
[Anonymous], 2008, CHINA NEWS
[4]  
Butantan S. I., NOVEL CORONAVIRUS IN
[5]   The race for coronavirus vaccines: a graphical guide [J].
Callaway, Ewen .
NATURE, 2020, 580 (7805) :576-577
[6]  
CDC Foundation, PUBLIC HLTH CONNECTS
[7]   Genomic variance of the 2019-nCoV coronavirus [J].
Ceraolo, Carmine ;
Giorgi, Federico M. .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (05) :522-528
[8]   COVID-19 control in China during mass population movements at New Year [J].
Chen, Simiao ;
Yang, Juntao ;
Yang, Weizhong ;
Wang, Chen ;
Barnighausen, Till .
LANCET, 2020, 395 (10226) :764-766
[9]   Risk communication, the West Nile virus epidemic, and bioterrorism: Responding to the communication challenges posed by the intentional or unintentional release of a pathogen in an urban setting [J].
Covello, VT ;
Peters, RG ;
Wojtecki, JG ;
Hyde, RC .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2001, 78 (02) :382-391
[10]  
Dai X. Y, 2020, J HENAN U SOCIAL SCI, V60, P26